Comparison of confirmed COVID‐19 with SARS and MERS cases ‐ Clinical characteristics, laboratory findings, radiographic signs and outcomes: A systematic review and meta‐analysis

Abstract

Introduction: Within this large-scale study, we compared clinical symptoms, laboratory findings, radiographic signs, and outcomes of COVID-19, SARS, and MERS to find unique features. Method:We searched all relevant literature published up to February 28, 2020.Depending on the heterogeneity test, we used either random or fixed-effect models to analyze the appropriateness of the pooled results. Study has been registered in the PROSPERO database (ID 176106).Result: Overall 114 articles included in this study; 52 251 COVID-19 confirmed patients (20 studies), 10 037 SARS (51 studies), and 8139 MERS patients (43 studies) were included. The most common symptom was fever; COVID-19 (85.6%, P < .001), SARS (96%, P < .001), and MERS (74%, P < .001), respectively. Analysis showed that 84% of Covid-19 patients, 86% of SARS patients, and 74.7% of MERS patients had an abnormal chest X-ray. The mortality rate in COVID-19 (5.6%, P < .001) was lower than SARS (13%, P < .001) and MERS (35%, P < .001) between all confirmed patients. Conclusions: At the time of submission, the mortality rate in COVID-19 confirmed cases is lower than in SARS-and MERS-infected patients. Clinical outcomes and findings would be biased by reporting only confirmed cases, and this should be considered when interpreting the data.

Incidence of Post-Traumatic Stress Disorder after Coronavirus Disease

“…The incidence of PTSD after COVID-19 (20%) is lower than that after MERS or SARS [14]. Although this could be explained by differences in the duration between the outbreak and the investigation of the presence of PTSD, it is also possible that the lower mortality rate (2-5%) for individuals with PTSD due to COVID-19 compared with the higher rates (10-20%) in MERS or SARS, could have affected the lower incidence of PTSD in COVID-19 [15].…”

Chemoprophylaxis, diagnosis, treatments, and discharge management of COVID-19: An evidence-based clinical practice guideline (updated version)

“…Compared to severe patients, moderate patients were less frequent to show the following features: traction bronchiectasis (OR = 0.40, 95% CI 0.24-0.67, P = 0.002), consolidation (OR = 0.31, 95% CI 0.15-0.64, P = 0.001), interlobular septal thickening (OR = 0.27, 95% CI 0.14-0.51, P = 0.000), crazy-paving pattern (OR = 0.22, 95% CI 0.11-0.44, P = 0.000), reticulation (OR = 0.20, 95% CI 0.05-0.80, P = 0.023), pleural effusion (OR = 0.19, 95% CI 0.07-0.49, P = 0.001), lymphadenopathy (OR = 0.17, 95% CI 0.07-0.41, P = 0.008), over 2 lobes involved (OR = 0.07, 95% CI 0.03-0.17, P = 0.000), but moderate patients were more likely to have radiographic abnormalities with 1 lobe involved (OR = 13.84, 95% A systemic review and meta-analysis (included 52,251 COVID-19 confirmed patients from China) showed that 84% (95% CI 0.78-0.85) of COVID-19 patients had abnormal radiological findings on chest X-ray and CT scans. The radiological abnormalities of bilateral involvement were 76.8% (95% CI 0.63-0.87), consolidation were 75.5% (95% CI 0.51-0.91), GGOs were 71% (95% CI 0.4-0.9), unilateral involvement were 16.5% (95% CI 0.85-0.30) [48].…”

Predictive criteria of severe cases in COVID‐19 patients of early stage: A retrospective observational study

“…Although previous studies suggested that the basic reproduction number (R0) of SARS‐CoV‐2 was between 2 and 3, the countries with prompt isolation were successful in reducing the reproduction number 1 . Extensive research has shown that the total mortality rate is 5.6%, lower than SARS (13%) and MERS (35%) 2 . But the death toll has far exceeded.…”